PGEN
Revolutionizing Respiratory Papillomatosis Treatment: Precigen Achieves Landmark Commercial Launch Milestone with Papzimeos
Precigen has made history in the medical field with its pioneering commercial launch of Papzimeos, a groundbreaking therapeutic agent for adult recurrent respiratory papillomatosis (RRP). In a significant milestone for patients and healthcare providers alike, this first-ever therapeutic commercial launch in RRP marks a substantial advancement in the treatment landscape.